Integrated AI-Guided de novo CDR-H3 Design and Combinatorial Phage Display for Antibody Discovery

Abstract Background Obtaining target-specific therapeutic antibodies is critical for maximizing efficacy, yet conventional library-based approaches cannot guarantee epitope specificity or enable straightforward humanization; computational de novo design of human antibodies targeting specific epitopes has therefore attracted increasing interest. Methods We developed SANDAN (Structure-Aware de Novo Design for ANtibody), an end-to-end, structure-driven workflow that uses the antigen structure and epitope residues without supplying a known binding antibody or its complex pose as design input. Starting from a human framework with diverse CDR-H2 and CDR-L3 variants, the workflow performs CDR-H3-focused design using the diffusion-based method DiffAb on diverse template complex structures predicted by Boltz-1, aiming to obtain antibodies that bind specifically to the target epitope without requiring known complex pose information. Targeting human TIGIT (hTIGIT), we selected approximately 1,000 CDR-H3 design sequences and constructed a phage display library (diversity approximately ${10}^6$) incorporating them. Results Screening yielded six hTIGIT-binding antibodies that competed with the reference antibody MG1131. Their CDR-H3 sequences differed from that reference antibody’s CDR-H3 sequence. Conclusions Combining AI-guided CDR-H3 design with phage display screening yielded hTIGIT-binding antibodies that competed with MG1131 from a combinatorial library containing the designed H3 sequences.

Authors

Institutions

Publication Details

Journal
Antibody Therapeutics
Published
2026-10-27
DOI
https://doi.org/10.1093/abt/tbag054
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integrated AI-Guided de novo CDR-H3 Design and Combinatorial Phage Display for Antibody Discovery

Kairi Furui, Takatsugu Kosugi, Kana Gondo, Takuya Shimomura et al.
4 links
Antibody Therapeutics
Monoclonal and Polyclonal Antibodies Research
article

Integrated AI-Guided de novo CDR-H3 Design and Combinatorial Phage Display for Antibody Discovery

Kairi Furui, Takatsugu Kosugi, Kana Gondo, Takuya Shimomura, Masahito Ohue, Rika Yamazaki, Shinji Soga, K. Uchikawa, Shigenori Yagi
article en

Abstract

Abstract Background Obtaining target-specific therapeutic antibodies is critical for maximizing efficacy, yet conventional library-based approaches cannot guarantee epitope specificity or enable straightforward humanization; computational de novo design of human antibodies targeting specific epitopes has therefore attracted increasing interest. Methods We developed SANDAN (Structure-Aware de Novo Design for ANtibody), an end-to-end, structure-driven workflow that uses the antigen structure and epitope residues without supplying a known binding antibody or its complex pose as design input. Starting from a human framework with diverse CDR-H2 and CDR-L3 variants, the workflow performs CDR-H3-focused design using the diffusion-based method DiffAb on diverse template complex structures predicted by Boltz-1, aiming to obtain antibodies that bind specifically to the target epitope without requiring known complex pose information. Targeting human TIGIT (hTIGIT), we selected approximately 1,000 CDR-H3 design sequences and constructed a phage display library (diversity approximately ${10}^6$) incorporating them. Results Screening yielded six hTIGIT-binding antibodies that competed with the reference antibody MG1131. Their CDR-H3 sequences differed from that reference antibody’s CDR-H3 sequence. Conclusions Combining AI-guided CDR-H3 design with phage display screening yielded hTIGIT-binding antibodies that competed with MG1131 from a combinatorial library containing the designed H3 sequences.

Antibody Therapeutics
Tokyo Institute of Technology (JP), Astellas Pharma (Japan) (JP), Institute of Science Tokyo (JP)
Astellas Pharma, Japan Society for the Promotion of Science, ACT-X
Good health and well-being
Openalex Percentile: Top 13%
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon